文献速递头颈外科

COVID-19大流行前及期间美国头颈癌发病率变化

Head and Neck Cancer Incidence in the United States Before and During the COVID-19 Pandemic.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2024-01-01

这项基于SEER登记的横断面研究分析了2017至2020年美国口腔、咽及喉癌发病率,发现2020年大流行第一年局限性头颈癌发病率下降,晚期头颈癌总体发病率无变化,作者提出后续年份可能观察到晚期诊断增加。

要点

  • 2020年局限性头颈癌发病率较2019年下降7.9%(95%CI,-7.5至-8.2)。
  • 男性、西班牙裔及喉癌患者的局限性癌发病率下降幅度最大。
  • 晚期头颈癌总体发病率在2020年未见变化。

核心结论

  • 在这项横断面研究中,大流行第一年局限性头颈癌发病率下降;作者提出后续年份可能观察到晚期诊断的增加。

研究设计与样本

  • 横断面研究,纳入2017至2020年美国SEER癌症登记中诊断的口腔、咽(口底、牙龈及其他口腔、唇、口咽及扁桃体、舌)和喉癌患者。
  • 亚组分析按种族和 ethnicity、年龄及性别分层;数据分析于2023年4月最新更新后进行。

主要发现

  • 2019年美国口腔和咽癌估计诊断21 664例(15 341例[71%]男性;10 726例[50%]≥65岁),2020年为20 390例(4355例[70%]男性;10 393例[51%]≥65岁)。
  • 头颈癌总体发病率从2019年每10万人11.6例降至2020年10.8例。
  • 局限性癌发病率从2019年至2020年降至8.8例(-7.9%[95%CI,-7.5至-8.2])。
  • 大流行第一年局限性癌发病率下降幅度最大者为男性患者(-9.3%[95%CI,-9.2至-9.5])、西班牙裔患者(-12.9%[95%CI,-12.9至-13.0])和喉癌患者(-14.3%[95%CI,-13.6至-15.0])。
  • 晚期头颈癌总体发病率未见变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Research about population-level changes in the incidence and stage of head and neck cancer (HNC) associated with the COVID-19 pandemic is sparse. OBJECTIVE: To examine the change in localized vs advanced HNC incidence rates before and during the first year of the pandemic. DESIGN, SETTING, AND PARTICIPANTS: In this cross-sectional study of patients in the US diagnosed with HNC from 2017 to 2020, the estimated number with cancer of the oral cavity and pharynx (floor of mouth; gum and other mouth; lip; oropharynx and tonsil; and tongue) and larynx were identified from the SEER cancer registry. Subgroup analyses were stratified by race and ethnicity, age, and sex. Data were analyzed after the latest update in April 2023. EXPOSURE: The COVID-19 pandemic in 2020. MAIN OUTCOMES AND MEASURES: The primary outcomes were the annual incidence rates per 100 000 people for localized HNC (includes both localized and regional stages) and advanced HNC (distant stage) and weighted average annual percentage change from 2019 to 2020. Secondary outcomes included annual percentage change for 2017 to 2018 and 2018 to 2019, which provided context for comparison. RESULTS: An estimated 21 664 patients (15 341 [71%] male; 10 726 [50%] ≥65 years) were diagnosed with oral cavity and pharynx cancer in 2019 in the US, compared with 20 390 (4355 [70%] male; 10 393 [51%] ≥65 years) in 2020. Overall, the HNC incidence rate per 100 000 people declined from 11.6 cases in 2019 to 10.8 in 2020. The incidence rate of localized cancer declined to 8.8 cases (-7.9% [95% CI, -7.5 to -8.2]) from 2019 to 2020. The localized cancer incidence during the first year of the pandemic decreased the most among male patients (-9.3% [95% CI, -9.2 to -9.5]), Hispanic patients (-12.9% [95% CI, -12.9 to -13.0]), and individuals with larynx cancer (-14.3% [95% CI, -13.6 to -15.0]). No change in the overall incidence rate was found for advanced HNC. CONCLUSIONS AND RELEVANCE: In this cross-sectional study, the incidence of localized HNC declined during the first year of the pandemic. A subsequent increase in advanced-stage diagnoses may be observed in later years.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Semprini J, Pagedar NA, Boakye EA, et al. Head and Neck Cancer Incidence in the United States Before and During the COVID-19 Pandemic. JAMA Otolaryngol Head Neck Surg. 2024. PMID: 38206603. doi:10.1001/jamaoto.2023.4322

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。